img-6381_edited_edited_edited.jpg

TECHNOLOGY

Philosophy

Candy Cotton

Technology and the Foundation of Cenyx

Nanozymes were applied to acute CNS disease

Lee Seung-hoon, CEO of Cenyx Biotech Inc, demonstrated the high potential of nanozyme medicine by studying the treatment of acute CNS disease by application of nanozymes.
In 2012, Lee Seung-hoon's research team published a study in Angewandte Chemie, a world-leading journal in nanoparticles, demonstrating that the size of cerebral infarctions decreased when nanozymes was applied to cerebral infarctions in animal models. This seminal study broadcast the excellence and applicability of nanozymes across academia.

img_0047_edited.jpg

10 Years of

Nanozyme research

0001.jpg
adhm201801548-gra-0001-m.jpg

2012 cerebral infarction

Kim CK, Lee SH et al., Angew Chem 2012

Sepsis 2017-SIRS

Kang DW, Lee SH et al., Angew Chem 2017

Sepsis 2019-SIRS

Jeong HG, Lee SH et al., Adv Healthcare Mat 2019

10 Years of

Nanozyme research

CEO Lee Seung-hoon, who succeeded in developing nanozyme medicines that exhibited excellent therapeutic effects for cerebral infarction, has strived over the past decade to answer the question, "Couldn't nanozymes with strong therapeutic effects help solve other severe acute diseases?"
In response, Cenyx Biotech has achieved multiple successes, proving the therapeutic effectiveness of nanozymes in treating intracerebral hemorrhage (in 2017), subarachnoid hemorrhage (in 2018), and sepsis (in 2019), in animal models.

0001.jpg
0001.jpg
adhm201801548-gra-0001-m.jpg

2012 cerebral infarction

Kim CK, Lee SH et al., Angew Chem 2012

Sepsis 2017-SIRS

Kang DW, Lee SH et al., Angew Chem 2017

Sepsis 2019-SIRS

Jeong HG, Lee SH et al., Adv Healthcare Mat 2019

Lee SH et al. Stroke 2018;49:3030-3038

이미지 클릭 시 해당 논문의 원본으로 된 사이트로 이동합니다.
  • 2012.11 Ceria nanoparticles that can protect against ischemic stroke.Angew Chem Int Ed Engl. 2012;51:11039-43)
     

  • 2017.08 Published the world's first proof of the effectiveness of cerium oxide nanozymes to treat cerebral hemorrhage
     

  • 2018.02 World's first announcement of the treatment effect of cerium oxide nanozyme on subarachnoid hemorrhage and receiving Basic Science Award
     

  • 2018.12 Ceria nanoparticles synthesized with aminocaproic acid for the treatment of subarachnoid hemorrhage.Stroke. 2018;49:3030-3038)
     

  • Published as the cover paper of'Stroke', an international academic journal in the field of stroke in 2018
     

  • 2019.03 Ceria nanoparticles fabricated with 6-aminohexanoic acid that overcome systemic inflammatory response syndrome.Adv Healthc Mater. 2019:e1801548)

이미지 제공: NASA

Beyond the lab and into the wider world

 Beyond First-in-class

Nanozyme, which was first introduced to the world, focuses on the function of a catalyst and has high functionality,

There were many limitations to apply for treatment.

 

Cenyx Biotech is developed in the laboratory with the aim of Proof of concept ,

Through the second-generation nanozyme , which has proven its value through various research results,

 

We have succeeded in developing the

3rd generation nanozyme

which was developed as a more powerful and safer treatment than the previous generation nanozyme.

대문이미지(4)_최종.jpg

First mover in nanozyme technology

Cenyx Biotech is pioneering a new first avenue to treat various acute diseases with first-in-material nanozymes .